Skip to main content

Cancer Genomic Profiling with the Resolution ctDx Platform

Agilent is a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions, with more than 70 custom assays developed with pharma, biotech, and research institutions.

The ctDx portfolio of liquid biopsy assays provides clinicians and researchers with tumor genomic profiling information. Pharmaceutical companies looking for a companion diagnostic (CDx) development partner can also leverage the Agilent Resolution ctDx platform to create custom panels for their targeted therapy or immunotherapy program. The assays are performed as a service in our state-of-the-art Agilent Resolution Clinical Laboratory Improvement Amendments (CLIA)-certified lab based in Kirkland, Washington.